Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

AMAG Pharmaceuticals Announces Appointment of Barbara Deptula to Board of Directors

AMAG Pharmaceuticals Announces Appointment of Barbara Deptula to Board of

LEXINGTON, Mass., Sept. 9, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.
(Nasdaq:AMAG) today announced that Barbara Deptula, former executive vice
president and chief corporate development officer of Shire plc, has been
elected to AMAG's Board of Directors, effective September 6, 2013.

Ms. Deptula brings to the AMAG board broad-based corporate development
expertise obtained through her distinguished 30-year career in a variety of
biotechnology and multi-national pharmaceutical organizations. During her
tenure at Shire, the company deployed nearly five billion dollars acquiring a
range of companies and products, and established an independent venture
capital arm.

"Barbara has had a successful career as a senior executive in business
development and corporate strategy, and she brings to our board a skill set
that complements our current board and AMAG's strategic focus," said Michael
Narachi, chairman of the board of AMAG. "We are pleased to have Barbara join
us as we continue to grow our current products and seek additional products to
add to our portfolio."

Ms. Deptula began working at Shire Pharmaceuticals in 2004, and retired in
2012 from her position as executive vice president and chief corporate
development officer, and a member of Shire's leadership team. Prior to joining
Shire, Ms. Deptula was president of the biotechnology division of Sicor Inc.
and senior vice president for commercial and product development at Coley
Pharmaceutical Group. She also held senior management positions focused on
marketing, product development, licensing and business development at US
Bioscience, Schering Plough, American Cyanamid, and Genetics Institute. Ms.
Deptula received her master's degree in business administration from the
University of Chicago and a bachelor's of science degree from the University
of Connecticut's School of Pharmacy.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets
Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in
the United States. Along with driving organic growth of its products, AMAG
intends to expand its portfolio with additional commercial-stage specialty
products. The company is seeking complementary products that leverage the
company's commercial footprint and focus on hematology and oncology centers
and hospital infusion centers. For additional company information, please

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc.; MuGard is a registered trademark of Access
Pharmaceuticals, Inc.

CONTACT: AMAG Pharmaceuticals Contact:
         Amy Sullivan, 617-498-3303
Sponsored Links
Sponsored Links